Objective-CTX0E03 (CTX) is a clinical-grade human neural stem cell (hNSC) line that promotes angiogenesis and neurogenesis in a preclinical model of stroke and is now under clinical development for stroke disability. We evaluated the therapeutic activity of intramuscular CTX hNSC implantation in murine models of hindlimb ischemia for potential translation to clinical studies in critical limb ischemia. Approach and Results-Immunodeficient (CD-1 Fox nu/nu ) mice acutely treated with hNSCs had overall significantly increased rates and magnitude of recovery of surface blood flow (laser Doppler), limb muscle perfusion (fluorescent microspheres, P<0.001), and capillary and small arteriole densities in the ischemic limb (fluorescence immunohistochemistry, both P<0.001) when compared with the vehicle-treated group. Hemodynamic and anatomic improvements were dose related and optimal at a minimum dose of 3×10 5 cells. Dose-dependent improvements in blood flow and increased vessel densities by hNSC administration early after ischemia were confirmed in immunocompetent CD-1 and streptozotocin-induced diabetic mice, together with marked reductions in the incidence of necrotic toes (P<0.05). Delayed administration of hNSCs, 7 days after occlusion, produced restorative effects when comparable with acute treatment of 35 days after hindlimb ischemia. Histological studies in hindlimb ischemia immunocompetent mice for the first 7 days after treatment revealed short-term hNSC survival, transient elevation of early host muscle inflammatory, and angiogenic responses and acceleration of myogenesis. Conclusions-hNSC therapy represents a promising treatment option for critical limb ischemia. (Arterioscler Thromb Vasc Biol. 2014;34:408-418.)
C ritical limb ischemia (CLI) and ischemic stroke are common manifestations of atherosclerosis and vascular occlusion of peripheral and cerebral arteries, respectively, leading to cell death and tissue necrosis. CLI is characterized by pain at rest, nonhealing wounds, and gangrene, progressing to loss of limb and high rates of mortality. The leading risk factors of CLI are diabetes mellitus and age. Currently, there are no effective pharmacological interventions to treat CLI. Revascularization through endovascular or surgical techniques to improve patency of the affected region is only tenable in half of the patients with CLI with the achieved patency failing in 30% of cases within 1 year. 1 Approximately 50% of all CLI patients die within 1 year of diagnosis. The incidence of CLI in the Western world is ≈220 new cases per million people per year, and the population at risk is expected to increase with aging and the increase in type II diabetes mellitus. 2, 3 There is clearly a need to develop new therapies to restore blood flow and rescue limbs in patients with CLI.
See accompanying editorial on page 237
A growing therapeutic strategy for CLI is the promotion of neovascularization either by delivery of proangiogenic factors or cell therapy. The rationale of the approach is to encourage spontaneous neovascularization, which is impaired in aged or diseased patients. 4 Gene therapies, for example, vascular endothelial growth factor (VEGF) and fibroblast growth factor, have been developed to promote neovascularization in ischemic tissues; however, phase II clinical trials did not show consistent improvements in amputation-free survival. 4 There are several possible reasons for these poor outcomes, including short half-lives of vectors and possible immune/inflammatory responses to the virus. It has also been noted that the elevated production of a single growth factor can lead to the defective structure of the newly formed capillaries. 5 Several preclinical studies in the hindlimb ischemia (HLI) model with administration of cells derived from blood, bone marrow, and skin have demonstrated vascular and muscle regeneration and tissue healing. 4, [6] [7] [8] These results have led to multiple small clinical trials in which autologous bloodderived or bone-marrow-derived mononuclear cells were administered to patients with CLI. 9, 10 A meta-analysis of randomized controlled trials has shown increased amputationfree survival time and improved wound healing in cell-treated patients when compared with those of the placebo arm. 11 However, there are limitations to the use of autologous sources for cell therapy products. Harvest of bone marrow requires invasive apheresis and a lengthy bespoke Good Manufacturing Practice process. This approach often leads to cells of variable quality and potency that are affected by the patient's age and disease status and to inconsistent therapeutic outcomes. 2, 12 CTX-drug product is a manufactured allogeneic product of consistent quality derived from a conditionally immortalized clonal human neural stem cell (hNSC) line. The CTX cell line is genetically modified to permit the generation of genetically and phenotypically stable cell banks. 13 The safety of CTX hNSC treatment is currently being assessed in disabled patients with stroke (Pilot Investigation of Stem Cells in Stroke [PISCES] trial, NCT01151124).
In vitro, hNSCs give rise to all differentiated neural cells, but in vivo, the cells also deliver paracrine mediators that modulate inflammation and stimulate angiogenesis and neurogenesis in animal models of stroke. 14, 15 These activities have therapeutic potential for the treatment of both stroke and CLI. The aim of the current research is to test the efficacy of clinical-grade CTX hNSC therapy in the murine HLI model in preparation of first-in-human clinical studies in patients with CLI.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Intramuscular Injection of hNSCs Improves Perfusion and Angiogenesis in the Ischemic Limb of Immunodeficient Mice
Laser Doppler measurement showed a reduction of limb blood flow in all experimental groups shortly after occlusion of the femoral artery. This was followed by progressive recovery of blood flow, which was more pronounced in hNSC-treated groups (P<0.01 versus vehicle, 2-way ANOVA; Figure 1A and 1B). Similarly, fluorescent microsphere measurement of adductor muscle blood flow confirmed the improvement by hNSC therapy when compared with that of vehicle (P<0.001, ANOVA), with no differences among cell doses thus suggesting achievement of a maximal therapeutic effect at the lowest tested dose of 3×10 5 hNSCs ( Figure 1C ). There was no significant difference in blood flow between the vehicle-and the cell-treated groups in the contralateral limb (data not shown). Furthermore, all 3 cell-treated groups showed increased capillary and small arteriole densities in the ischemic limb muscles, as assessed by immunofluorescence staining (P<0.001 for both measures, ANOVA; Figures 1D-1F ). This difference was not seen in the contralateral limb (data not shown).
Titration of Dosage Effects on Clinical and Anatomic End Points
We next investigated whether there is a relation between cell dosage and therapeutic end points using a range of doses below those tested in the previous experiment. We confirmed that hNSC administration induces a significant improvement in limb blood flow when compared with vehicle (laser Doppler, P<0.001, 2-way ANOVA; fluorescent microsphere measurements, P<0.0001; Figure 2A and 2B). This effect was proportional to the cell dose with regard to both measurements (P<0.01 and P<0.001, Linear trend, respectively; Figure 2A and 2B). There were no significant differences between groups in limb or muscle blood flow in the contralateral limb (data not shown). To verify whether the enhanced perfusion improves tissue oxygenation, the tissue oxygen pressure (TpO 2 ) was measured at the end of the study. We found this parameter to be improved in hNSC-treated mice, with this effect being dose related (P<0.0001 ANOVA, P<0.001, Linear trend) and with only the highest dose being significantly different from the vehicle (P<0.01; Figure 2C ). There was also a significant cell treatment effect and a dose effect on capillary density and arteriole density in the ischemic muscle (P<0.0001 ANOVA, P<0.0001, Linear trend, for both comparisons; Figure 2D and 2E). It should be noted that the low-dose groups had significantly lower capillary and arteriole densities but not reduced blood flow or TpO 2 when compared with the vehicle group.
Intramuscular Injection of hNSCs Improves Postischemic Recovery in Immunocompetent Mice and Streptozotocin-Induced Diabetic Mice
The efficacy of hNSC implantation was evaluated in immunocompetent CD-1 mice, comparing streptozotocin-induced diabetic with nondiabetic mice. Both diabetic and nondiabetic mice had similar incidences of toe necrosis on the ischemic hindlimb within the first 7 days after ischemia; therefore, these data were analyzed as a single data set ( Figure 3 ). Importantly, hNSC implantation reduced the number of mice presenting with necrotic toes (χ 2 , P<0.05). This effect was statistically significant in the intermediate (3×10 5 ) and in the high cell dose (1.5×10 6 ) groups (P<0.01 and P<0.01 both; P<0.01 Logrank trend) but not in the low-dose group (Figure 3 ). There was also a reduction in the severity and number of necrotic toes per mouse with cell treatment (data not shown).
Laser Doppler assessment of blood flow showed progressive recovery of blood flow in nondiabetic hindlimbs until the 21-day laser Doppler assessment ( Figure 4A and 4B), whereas it plateaued from 7 days onward in the corresponding diabetic group, indicating a deficit in late reperfusion ( Figure 4C and 4D). hNSC treatment not only accelerated the recovery but also alleviated the difference between diabetic and nondiabetic groups, showing comparable improvement in both the groups (P<0.001, 2-way ANOVA; P<0.001, Linear trend; Figure 4B and 4D). Likewise, fluorescent microsphere measurement of adductor muscle blood flow at 21 days after ischemia demonstrated a reduced perfusion of ischemic and contralateral adductors in diabetic mice when compared with muscles of nondiabetic controls (P<0.001, ANOVA both limbs; Figure 5A and 5B). hNSC treatment significantly increased muscle blood flow in the ischemic limb of both diabetic and nondiabetic mice (P<0.001, ANOVA). This effect was dose related (P<0.001, Linear trend; Figure 5A ). However, no change was observed in contralateral muscles ( Figure 5B ). The benefit of hNSC treatment was further confirmed by the measurement of muscular oxygenation. There was a diabetes-related effect with lower TpO 2 in the ischemic limbs when compared with the nondiabetic controls (P<0.001, ANOVA; Figure 5C ), which was improved by hNSC treatment (P<0.001, ANOVA) that was dose dependent (P<0.001, Linear trend; Figure 5C ).
Immunofluorescence analysis showed that capillary and arteriole densities in adductor muscles of vehicle-treated diabetic mice were lower when compared with nondiabetic controls (P<0.001 capillaries, P=0.005 arterioles, ANOVA; Figure 5D and 5E). hNSC treatment significantly increased both capillary ( Figure 5D ) and arteriole density ( Figure 5E ) in the ischemic limb of both diabetic and nondiabetic groups (P<0.01 and P<0.001, respectively, ANOVA). These proangiogenic effects were dose dependent (P<0.001 both measures, Linear trend).
A pairwise comparison of the effect sizes across the functional and anatomic measures in the diabetic and nondiabetic mice was performed. This comparison demonstrated a significantly greater response to hNSC treatment in the diabetic mice (P=0.001, paired t test).
Delayed hNSC Treatment Produces Comparable Functional and Anatomic Effects to Acute Administration
Next, we investigated whether late application of cell therapy is as effective as acute treatment after induction of ischemia. Here, the aim was to address the clinically relevant question of efficacy under conditions of chronic hypoperfusion that represent the common setting for cell therapy in patients. In addition, we compared hNSCs with alternative stem cell type, human mesenchymal stem cells (hMSCs), delivered acutely and tested >35 days after ischemia.
In the acute administration study, mice treated with hNSCs or hMSCs (3×10 5 ) on the day of ischemia showed significantly increased limb blood flow recovery when compared with vehicle-treated mice (P<0.001, 2-way ANOVA; Figure 6A ). The improvement was evident from 7 to 35 days, suggesting that the effect of cell therapy is long lasting. In the delayed administration study, mice treated with hNSCs 7 days after ischemia showed increased blood flow in the ischemic muscle when compared with vehicle-treated mice (P<0.0001, ANOVA; Figure 6B ), matching the results of acute hNSC treatment.
In addition, both hNSCs and hMSCs improved muscular TpO 2 (P<0.0001, ANOVA; Figure 6C ). There were no significant differences among groups with regard to the TpO 2 of the contralateral limb (data not shown). Delayed administration of hNSCs improved the ischemic muscle TpO 2 to the same extent as acute treatment (P<0.0001; Figure 6C ).
Capillary density in the affected limb was significantly greater in the hNSC-treated group when compared with vehicle-treated group in both the acute and the delayed administration studies (P<0.05 for both comparisons; Figure 6D ), which was not observed with hMSCs treatment ( Figure 6D ). In contrast, arteriole density was increased by delayed administration of hNSCs (P<0.01), with no significant change with acute hNSC treatment, whereas acute hMSC administration resulted in a significant increase (P<0.05; Figure 6E ).
In Vivo hNSC Persistence
The persistence of implanted cells in studies 1 to 4 was determined at 21 or 35 days after treatment by immunohistochemistry of serial sections collected throughout the entire muscle of vehicle-and cell-treated mice using human-specific nestin or mitochondrial antibodies. A low incidence and number of surviving hNSCs were observed across studies ( Table III in the onlineonly Data Supplement). Where hNSCs were present, they were located in discrete sites, with <20 to 50 cells present per section.
In study 5, immunohistochemical analysis of hNSC survival (0-7 days) in HLI CD-1 mice demonstrated timerelated loss of cells after implantation: ≈90% of the original cellular implant was lost by 24 hours after implantation with no cells present at 7 days ( Figure 7A , i). Most surviving hNSCs expressed cleaved caspase-3 ≤72 hours after implantation, indicating that cell loss was because of apoptosis ( Figures 7A, ii) .The small number of host CD3-positive T cells detected at the site of implantation but not within the implant itself, suggested hNSC loss was not because of immune rejection ( Figure 8A ).
Characterization of Implanted Cell Phenotype
To clarify the phenotype of hNSCs and ensuing host responses in ischemic muscles, we identified the implanted cells by fluorescent immunostaining with antibodies against human mitochondria or nestin and antibodies against markers of inflammation, adhesion/migration and tissue repair ( Table  IV in the online-only Data Supplement). Figure 7B , i and ii shows hNSCs coexpressing human antigens and CD44 (i) or PAX-7 (ii), which are adhesion and myogenesis markers, respectively. Figure 7B , iii indicates that a high percentage of implanted hNSCs coexpressed the inflammatory markers tumor necrosis factor-α and interferon-γ immediately and ≤72 hours after implantation. Expression of interleukin-6 (IL-6), a proinflammatory cytokine, was short-lived and was only displayed by hNSCs ≤24 hours after implantation. NO synthase (NOS; isoform(s) not determined) was upregulated from 4 to 72 hours ( Figure 7B , iii).
Furthermore, both antigens shared by immune cells were expressed by implanted hNSCs ( Figure 7B , iv and Figure I in the online-only Data Supplement). All implanted hNSCs expressed CD68 at all time points (0, 4, 24, and 72 hours); in contrast, CD3 expression was lost with time: 84.6% at 0 hours, 80.4% at 4 hours, 51.1% at 24 hours, and 0% at 72 hours after implantation.
Markers of adhesion/migration (CD44 and CD29) were both expressed; however, CD44 was lost after 24 hours ( Figure 7B , v). In addition, markers of angiogenesis and muscle repair showed large changes: the angiogenic factor, VEGF, was expressed by all implanted cells ≤24 hours and then declined with time; the endothelial marker, Von Willebrand Factor showed an opposite trend, increasing 5-fold from very low basal levels; the myogenesis marker, PAX-7 was markedly upregulated with ≈70% of hNSCs expressing this marker at 72 hours after implantation ( Figure 7B , vi). hNSC-treated ischemic muscles ( Figure II in the online-only Data Supplement and Figure 8 ). In addition to the improved capillarization and arteriolization, as described previously, immunohistochemistry analysis revealed no difference in host CD3 or CD68 expression in the ischemic muscles between groups ( Figure 8A and 8B) . In contrast, hNSC-injected ischemic muscles had increased expression of IL-1β (P<0.01, 2-way ANOVA), Von Willebrand Factor (P<0.0001, 2-way ANOVA), and secretory leukocyte protease inhibitor (P<0.05, 2-way ANOVA; Figure 8C -8E) when compared with vehicleinjected muscles. In addition, hNSC administration caused an initial upregulation of host CD29 (P<0.01) and CD31 (P<0.001) but no changes in the CD44 expression ( Figure 8F-8H) .
Characterization of Host Response
Finally, diameter measurements of newly formed myocytes with centralized nuclei were used as a measure of muscle regeneration. Measurements were performed using image analysis software on hematoxylin and eosin-stained sections of 7-day ischemic adductor muscles (both hNSC and vehicle treated) from HLI CD-1 mice. hNSC administration significantly increased the diameter of the regenerating myofibers when compared with vehicle (P<0.01; Figure 9 ).
Effect of Cell Therapy on Host Gene Expression in Ischemic Muscles
Gene expression of 637 genes associated with inflammation was quantified using OpenArray. The results were expressed as a fold change of hNSC-injected over control ischemic muscle responses; biological significance was defined as ≥1.5-fold increase ( Figure 10 and Table V in the online-only Data Supplement). VEGFa 16 and hypoxia-inducible factor-1 α, 17 which play a major role in ischemia-induced new bloodvessel formation, were found to be significantly upregulated at all time points. Several other growth factors known to be related to angiogenesis and tissue repair were significantly upregulated by hNSC implants ≥2 time points: fibroblast growth factor 2, 16 fibroblast growth factor 11, IGF1, 18 bone morphogenetic proteins (Bmp)4, Bmp6, and Bmp8a. 19, 20 A significantly increased expression of Ccl2 and Cxcl12 21 was detected at 4 hours and 7 days, respectively. Both of these genes have been reported to stimulate cell proliferation and capillary tube formation. 22, 23 Macrophage colony-stimulating factor and CD14 that are expressed mainly by macrophages, proinflammatory cytokines, such as IL-6, IL-1β, and IL-15, along with stimulatory receptors, CD28 and CD86, were all significantly upregulated in ≥3 time points. CD274, involved in both interferon-γ response and regulation of T cells, was also significantly upregulated at 4 time points.
Discussion
The series of studies reported here consistently show that administration of hNSCs from the clinical-grade CTX cell line promotes functional and anatomic improvements, irrespective of model chronicity or immune status of the mouse. Study 1 demonstrated increased blood flow, tissue perfusion, and capillary and small arteriole densities in the ischemic limb at all doses used. Study 2 demonstrated a dose-response effect for a 2-log range. The highest dose (3×10 5 cells) demonstrated efficacy in all measures and, thereby, established a working dose for further studies. The lowest dosage tested (3×10 3 cells) was unable to produce any effect on angiogenesis but resulted in a mild increase in muscle perfusion but not oxygenation, which is possibly because of local vasodilation.
Study 3 used immunocompetent mice and streptozotocininduced diabetes mellitus to model diabetic comorbidity in patients with CLI. This model demonstrated disease effects in a number of parameters, including vascular dysfunction and long-term changes in blood flow. 24 Diabetes mellitus is associated with a loss of potency of mononuclear cells for repair 25 and the establishment of a systemic proinflammatory state. 26 Treatment with hNSCs in the diabetic model promoted neovascularization of the ischemic limb to a similar degree to that measured in the nondiabetic mice. Total blood flow remained reduced in the diabetic mice; however, the effect size afforded by cell administration was larger when compared with that from the nondiabetic mice. The working dose (3×10 5 ) was effective in both conditions, suggesting that hNSC therapy would be effective in patients with both diabetes mellitus and non-diabetes mellitus.
Comparison of the hNSCs cells with hMSCs indicated a similar improvement in blood flow. However, unlike hNSCs, MSCs did not significantly enhance new capillary growth. The delayed administration of hNSCs also promoted blood flow and neovascularization, indicating that the effect is not preservation of vasculature at the time of ligation, but it is genuine neovascularization.
hNSCs have been shown to support angiogenesis via release of factors in vitro and in vivo. 15, 27 Furthermore, the present data show that hNSCs express VEGFa after implantation into ischemic muscles.
There are limitations of the preclinical model that need to be considered. The HLI model is performed in relatively young mice, which contrasts with patients with peripheral artery disease who present with CLI in their older years. Diabetes mellitus and ensuing pathologies resulting from hyperglycemia were established in the mice >6 weeks compared with an average of 20 years in the clinic. However, the addition of diabetes mellitus to HLI did increase the chronicity of the model. In spite of this, hNSC administration consistently promoted blood flow and neovascularization in this model. Immunogenic potential of hNSCs seems low. There was comparable efficacy in both nude and wild-type CD-1 mice at the same dose level. There was no evidence of rejection of the cells either at early or later time points after implantation. CTX hNSCs do not express major histocompatibility complex class II and do not promote a sustained host cellular response. 13 Of CLI patients with nonhealing ulcers, 60% have a clinical infection in the wound, making immunosuppressant drug therapy unsuitable. 28 In the ongoing phase I stroke clinical study, patients receiving CTX-drug product were not placed on immunosuppression. Importantly, laboratory assessment of allo-responses in these patients has not indicated an antibody response to date.
In the current study, early transient increases in inflammatory cytokines, chemokines, and growth factor expression were observed in hNSC-treated ischemic muscle even though classic inflammatory cell responses were not affected. hNSCs seem to act via paracrine signaling, releasing factors that change and activate host cells to coordinate elements of tissue response and repair. Inflammatory markers selected for host response investigation, tumor necrosis factor-α, interferon-γ, and NOS were expressed by the implanted cells with expression of NOS and tumor necrosis factor-α increasing with time after implantation. These cytokines have all been implicated in stromal cell immunomodulatory functions. 25 NO also plays a role in the local microenvironment by suppressing T-cell function. Koponen et al 29 have reported an increase in host macrophage response after umbilical cord blood cell treatment in the same limb ischemia model. The major roles of this cell type are to initiate the innate immune response and then to promote regeneration. hNSC treatment enhanced the host tissue expression of IL-1β, Von Willebrand Factor, and secretory leukocyte protease inhibitor (SPLI), which was associated to an early upregulation of stromal CD29 and mononuclear expressing VEGFa. Implanted hNSCs also expressed classic immune cell markers, CD3 (typical marker of T lymphocytes) and CD68 (typical marker of mononuclear cells). Similar observations of neural stem cells expressing inflammatory markers have been previously reported. 30, 31 The inflammatory phenotype and function of hNSCs are most likely induced by the implantation into the ischemic environment. . Short-term fate and phenotype of implanted human neural stem cells (hNSCs). A, No hNSCs were detected at 7 days after implantation (study 5 data). Loss of hNSCs followed a 1-phase exponential decay curve (t½=10.18 hours; r 2 =0.9877; i. hNSCs undergo apoptosis after implantation as visualized in this representative image showing hNSCs detected with human mitochondria (green) colocalized with cleaved caspase-3 (red) and counterstained with Hoechst (blue; nuclei). Bar, 50 µm (ii). B, Representative images show implanted hNSCs dual labeled with human mitochondria (green) and CD44 (red; i) and human nestin (green) and PAX-7 (red), both counterstained with Hoechst (blue; ii), bar, 50 µm. Line graphs show that hNSCs display remarkable changes in the expression of markers associated with inflammation (iii), immunity (iv), adhesion and migration (v), and angiogenesis and muscle repair (vi) during the first 72 hours after implantation in ischemic limb muscles. Data expressed as % of hNSCs positive for the indicated marker.
hNSC treatment significantly increased the diameter of the regenerating myofibers at 7 days after HLI. Implanted cells also expressed IL-6 and PAX-7; both have been reported to play an important role in the activation of muscle satellite cells during the early phase of muscle regeneration. 29 Inflammation is the critical trigger in the process of muscle regeneration 32 ; therefore, the transient enhancement and acceleration of some of the key inflammatory responses should promote angiogenesis and muscle repair. This process is also seen in the brain as hNSC administration potentiates the host repair responses after ischemic stroke in a manner that is consistent with acting through paracrine pathways. 15 Moreover, these conclusions fully support the translation of intramuscular hNSCs to clinical application to assess the safety and potential therapeutic benefit in patients with CLI.
In conclusion, we demonstrate the therapeutic potential of hNSCs in a mouse HLI model. We show dose-dependent improvements in functional measures and vasculature densities. In addition, phenotypic and molecular analyses show modification of the early ischemic microenvironment, promoting vascular and muscular regeneration in parallel with dynamic phenotypic changes of the implanted hNSCs. Our findings support both the secretion of angiogenic factors by implanted hNSCs (paracrine effect) and an hNSC-mediated activation of host muscle cells to produce angiogenic factors, thereby promoting neovascularization in ischemic tissues (hNSC-mediated activation of tissue repair). These novel observations indicate a reciprocal cross-talk between the host and the implanted cells, a key mechanism for stem cell-mediated enhancement of endogenous tissue repair processes. The same cell product has already shown initial proof of safety in the first-in-human PISCES stroke trial. These results support the progression of hNSC product toward clinical application in patients with CLI. Figure 10 . Changes in gene expression induced by human neural stem cell (hNSC) implantation. Heat map representing color-coded fold changes of differentially expressed genes in cell-vs vehicle-injected ischemic muscles. Full gene list and statistical analysis can be found in Table V in the online-only Data Supplement.
